TD Cowen Downgrades Legend Biotech After Carvykti Sales Miss
TD Cowen cut Legend Biotech to Hold from Buy after weaker Carvykti sales, citing slower demand, safety concerns, and rising competition.
/ 1659 items
#XY↓
Moderna Surges 69% in 2026 as Cancer Vaccine Shows Five-Year Melanoma Survival Benefits
Moderna stock jumped as five-year data from its personalized cancer vaccine trial with Merck showed a 49% reduction in melanoma recurrence risk, boosting hopes for mRNA's future in oncology.
Why TransMedics Stock Fell — and Why Analysts Aren’t Worried
TransMedics shares dropped after FDA clearance of a rival liver perfusion system, but TD Cowen says the selloff is overdone and sees no real competitive threat.
Johnson & Johnson Q4 Earnings Beat, But Stock Falls on Stelara
Johnson & Johnson reports Q4 earnings of $2.46/share, beating estimates with 9.1% sales growth to $24.6B, but stock falls 3% on Stelara patent loss concerns.
Lisata Therapeutics Acquired by Kuva Labs for $4/Share
Kuva Labs to acquire Lisata at $4/share plus $2 in contingent payments—an 85% premium. Deal expected to close before Feb 27, 2026.
BofA Starts Coverage of Inhibikase Therapeutics with Buy Rating
BofA gives Inhibikase Therapeutics (IKT) a Buy rating with $6 target, citing strong data, regulatory support, and promising leukemia therapy for PAH.